Overall, 15.0% (n = 97) of RCC samples were PDL1+ (staining of ≥2+ intensity and ≥5% tumor cells using SP142 antibody), with significantly higher frequency of PDL1+ tumors in medullary (37.5%, n = 3; P < 0.05), MiT translocation (42.9%, n = 3; P < 0.05), papillary (24.2%, n = 14; P < 0.05), and mixed (26.5%, n = 9; P < 0.05) RCC compared with ccRCC (12.0%, n = 60; P < 0.05). The gene discussed is CD274; the disease is neoplasm.